We are developing a novel, high-performance long read sequencing assay, code named Infinity, that will provide the most comprehensive view of the genome, including SNPs, indels and structural variants.
This long read assay will feature:
Long-read sequencing is a highly accurate approach that can be used to:
Long-read sequencing technology has the potential to improve the efficiency and accuracy of many existing DNA sequencing applications while increasing the coverage of clinically important genes.
These advantages allow for the phased re‐sequencing of human genomes and rapid de novo sequencing of plant and animal genomes.
The Illumina Long-Read Applications Ecosystem is a group of partnerships dedicated to ensuring the delivery of high-quality data for fully featured genomes, including phasing, detection of structural variants, and de novo assembly of all species.
The combination of our core sequencing technology, along with our partners’ linked-read preps, assembly protocols, and analysis pipelines, are allowing Illumina to bring advanced long-read application solutions to the market. The Illumina Long-Read Ecosystem leverages the following partner products and services:
Understanding the variants associated with rare diseases can help researchers pinpoint the causes of genetic disorders.
Get a comprehensive base-by-base view of the unique genomic abnormalities in cancer.
Sequencing can help identify novel species, improve our food supply, and ensure a sustainable environment.